Celecoxib, Rofecoxib Chronically Treated Mice, with IL1beta, Aorta RNA-Seq

We screen for vascular off-target effects at therapeutic concentrations of celecoxib and rofecoxib using genomic approaches in a mouse model of vascular inflammatory responses. We assess whether therapeutic concentrations of celecoxib and rofecoxib might elicit distinct genomic effects in vivo in mice by comprehensive and unbiased analysis of the whole transcriptome sequencing. Drug specific differences in their expression profiles would be indicative of off-target effects. RNA-Seq 24 samples, mouse aorta. Treated with Celecoxib (100 mg/kg/day), Rofecoxib (50 mg/kg/day), or normal chow for three weeks then given IL-1beta stimulation. Mice were sacrificed four hours after IL-1beta stimulation. Eight biological replicates for each of the three conditions.